145 related articles for article (PubMed ID: 10199453)
1. Anaphylaxis from intraperitoneal infusion of cisplatin: a case report.
Ozgüroglu M; Demir G; Demirelli F; Mandel NM
Am J Clin Oncol; 1999 Apr; 22(2):172-3. PubMed ID: 10199453
[TBL] [Abstract][Full Text] [Related]
2. Anaphylactoid reactions with intraperitoneal cisplatin.
Hebert ME; Blivin JL; Kessler J; Soper JT; Oleson JR
Ann Pharmacother; 1995 Mar; 29(3):260-3. PubMed ID: 7606071
[TBL] [Abstract][Full Text] [Related]
3. Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles.
Ciesielski-Carlucci C; Leong P; Jacobs C
Am J Clin Oncol; 1997 Aug; 20(4):373-5. PubMed ID: 9256892
[TBL] [Abstract][Full Text] [Related]
4. Death from anaphylaxis to cisplatin: a case report.
Zweizig S; Roman LD; Muderspach LI
Gynecol Oncol; 1994 Apr; 53(1):121-2. PubMed ID: 8175010
[TBL] [Abstract][Full Text] [Related]
5. [Life threatening anaphylaxis after repeated cisplatin administration: case report and neu therapy concepts].
Berg K; Grundmann U; Villena-Heinsen C; Wilhelm W; Mertzlufft F
Zentralbl Gynakol; 1996; 118(12):684-8. PubMed ID: 9082708
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
[No Abstract] [Full Text] [Related]
7. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
[TBL] [Abstract][Full Text] [Related]
8. Anaphylaxis to cisplatin following nine previous uncomplicated cycles.
Basu R; Rajkumar A; Datta NR
Int J Clin Oncol; 2002 Dec; 7(6):365-7. PubMed ID: 12494253
[TBL] [Abstract][Full Text] [Related]
9. Technique of intraperitoneal chemotherapy using veress needle in patients with ovarian cancer.
Ramarajapalli ML; Kilara NG; Subramanyam M; Rao NA
Int J Gynecol Cancer; 2011 Nov; 21(8):1388-90. PubMed ID: 21997168
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal hyperthermic chemotherapy in ovarian cancer.
Gori J; Castaño R; Toziano M; Häbich D; Staringer J; De Quirós DG; Felci N
Int J Gynecol Cancer; 2005; 15(2):233-9. PubMed ID: 15823105
[TBL] [Abstract][Full Text] [Related]
11. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal chemotherapy in the management of ovarian cancer.
Ozols R
Semin Oncol; 1985 Sep; 12(3 Suppl 4):75-80. PubMed ID: 4048980
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
14. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma.
Sakuragi N; Nakajima A; Nomura E; Noro N; Yamada H; Yamamoto R; Fujimoto S
Gynecol Oncol; 2000 Dec; 79(3):420-3. PubMed ID: 11104613
[TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity reactions to intraperitoneal administration of carboplatin in ovarian cancer: the first report of a case.
Shukunami K; Kurokawa T; Kawakami Y; Kubo M; Kotsuji F
Gynecol Oncol; 1999 Mar; 72(3):431-2. PubMed ID: 10053120
[TBL] [Abstract][Full Text] [Related]
16. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
Ozols RF
Semin Oncol; 1995 Dec; 22(6 Suppl 15):1-6. PubMed ID: 8643963
[TBL] [Abstract][Full Text] [Related]
17. [Comparative study of different chemotherapy approaches for advanced epithelial ovarian cancer].
Chen YL; Liu YQ; Tang DH; Chu CN
Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):110-4. PubMed ID: 18683749
[TBL] [Abstract][Full Text] [Related]
18. [Intraperitoneal cisplatin chemotherapy for ovarian cancer].
Hayashi H; Nishii H; Ueda K; Kunitou S; Wada S; Takanashi H; Kobayashi S; Yasuda M
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2043-8. PubMed ID: 11791382
[TBL] [Abstract][Full Text] [Related]
19. Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
Nicoletto MO; Dalla Palma M; Donach ME; Gusella M; Cappetta A; Shams M; Marchet A; Nardin M; Pintacuda G; Di Maggio A; Marchesi M; Carli P; Fiduccia P; Artioli G; Nitti D
Tumori; 2010; 96(6):918-25. PubMed ID: 21388052
[TBL] [Abstract][Full Text] [Related]
20. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
